Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Misato Nagata"'
Autor:
Misato Nagata, Tatsuo Kimura, Tomohiro Suzumura, Yukimi Kira, Toshiyuki Nakai, Kanako Umekawa, Hidenori Tanaka, Kuniomi Matsuura, Shigeki Mitsuoka, Naruo Yoshimura, Takako Oka, Shinzoh Kudoh, Kazuto Hirata
Publikováno v:
Clinical Medicine Insights: Oncology, Vol 2013, Iss 7, Pp 31-39 (2013)
Externí odkaz:
https://doaj.org/article/153e09339a014e469b114b0d23d72974
Autor:
Misato Nagata1, Tatsuo Kimura1 kimutats@med.osaka-cu.ac.jp, Tomohiro Suzumura1, Yukimi Kira2, Toshiyuki Nakai1, Kanako Umekawa1, Hidenori Tanaka1, Kuniomi Matsuura1, Shigeki Mitsuoka1, Naruo Yoshimura1, Takako Oka, Shinzoh Kudoh1, Kazuto Hirata1
Publikováno v:
Clinical Medicine Insights: Oncology. 2013, Issue 7, p31-39. 9p. 2 Charts, 2 Graphs.
Autor:
Misato Nagata1, Tatsuo Kimura1 kimutats@med.osaka-cu.ac.jp, Tomohiro Suzumura1, Yukimi Kira2, Toshiyuki Nakai1, Kanako Umekawa1, Hidenori Tanaka1, Kuniomi Matsuura1, Shigeki Mitsuoka1, Naruo Yoshimura1, Takako Oka1, Shinzoh Kudoh1, Kazuto Hirata1
Publikováno v:
Clinical Medicine Insights: Oncology. 2012, Issue 6, p31-39. 9p. 2 Charts, 2 Graphs.
Autor:
Kanako, Umekawa, Tatsuo, Kimura, Shinzoh, Kudoh, Tomohiro, Suzumura, Misato, Nagata, Shigeki, Mitsuoka, Kuniomi, Matsuura, Takako, Oka, Naruo, Yoshimura, Yukimi, Kira, Kazuto, Hirata
Publikováno v:
Osaka city medical journal. 59(1)
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are routinely used to treat advanced non-small cell lung cancer (NSCLC) patients with activated EGFR mutations, and are associated with excellent response and improvement of pe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::a25809e3c479fb0655592d07b51093b3
https://pubmed.ncbi.nlm.nih.gov/23909081
https://pubmed.ncbi.nlm.nih.gov/23909081
Autor:
Naruo Yoshimura, Shinzoh Kudoh, Tomohiro Suzumura, Kanako Umekawa, Kuniomi Matsuura, Shigeki Mitsuoka, Kazuto Hirata, Yukimi Kira, Tatsuo Kimura, Misato Nagata, Toshiyuki Nakai, Takako Oka
Publikováno v:
BMC Research Notes
Background Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), routinely used to treat advanced non-small-cell lung cancer (NSCLC) patients with activated EGFR mutations, are associated with excellent response and improved perf
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9677e6549dbae610cdeeefb124bf24b9
https://doi.org/10.1186/1756-0500-6-139
https://doi.org/10.1186/1756-0500-6-139
Autor:
Tomohiro, Suzumura, Tatsuo, Kimura, Shinzoh, Kudoh, Kanako, Umekawa, Misato, Nagata, Hidenori, Tanaka, Shigeki, Mitsuoka, Naruo, Yoshimura, Yukimi, Kira, Kazuto, Hirata
Publikováno v:
Osaka city medical journal. 58(1)
Rash, liver dysfunction, and diarrhea are known as adverse events of erlotinib and gefitinib. However, clinical trials with gefitinib have reported different adverse events compared to those with erlotinib. In an in vitro study, cytochrome P450 (CYP)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::9a256b43f674fae1a0eaf10bbcaed19e
https://pubmed.ncbi.nlm.nih.gov/23094511
https://pubmed.ncbi.nlm.nih.gov/23094511
Autor:
Misato Nagata, Kanako Umekawa, Naruo Yoshimura, Kazuto Hirata, Toshiyuki Nakai, S. Kudoh, Shigeki Mitsuoka, Kuniomi Matsuura, Tomohiro Suzumura, T. Kimura
Publikováno v:
Annals of Oncology. 23:ix79-ix80
Background Malnutrition in non-small cell lung cancer (NSCLC) is associated with advanced stage of disease and is needed for careful choice of treatment. The epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are routinely used
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::259e70f629b1ff148b8d4b6da9b3e04a
https://doi.org/10.1016/s0923-7534(20)32754-x
https://doi.org/10.1016/s0923-7534(20)32754-x
Autor:
Naruo Yoshimura, Kazuto Hirata, Tatsuo Kimura, Misato Nagata, Toshiyuki Nakai, Hidenori Tanaka, Shigeki Mitsuoka, Tomohiro Suzumura, Shinzoh Kudoh, Kanako Umekawa, Masako Hosono Hosono, Takuhito Tada
Publikováno v:
Journal of Clinical Oncology. 31:7564-7564
7564 Background: To determine a recommended dose (RD) of chemoradiotherapy with use of involved-field conformal radiotherapy and accelerated hyperfractionation (AHF) for stage III non-small cell lung cancer (NSCLC). Methods: Eligible patients had unr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a9458701b5a6fdd11375491353f8e7ff
https://doi.org/10.1200/jco.2013.31.15_suppl.7564
https://doi.org/10.1200/jco.2013.31.15_suppl.7564
Autor:
Hiroaki Tanaka, Kuniomi Matsuura, Kazuto Hirata, T. Kimura, Naruo Yoshimura, Tomohiro Suzumura, Kanako Umekawa, Misato Nagata, Toshiyuki Nakai, S. Kudoh, Shigeki Mitsuoka
Publikováno v:
Annals of Oncology. 23:xi135
Background Amrubicin hydrochloride (AMR) is a novel synthetic aminoanthracycline derivative. AMR is metabolized to amrubicinol (AMR-OH), and the cytotoxic activity of AMR-OH is 18–220 times more potent than that of AMR. NADPH quinone oxidoreductase
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1db84a4b6cf084749d3d7f45db59d21e
https://doi.org/10.1016/s0923-7534(20)32395-4
https://doi.org/10.1016/s0923-7534(20)32395-4
Autor:
Misato Nagata, Tomohiro Suzumura, Toshiyuki Nakai, S. Kudoh, Shigeki Mitsuoka, Kazuto Hirata, T. Kimura, Yukimi Kira, Kanako Umekawa, Kuniomi Matsuura
Publikováno v:
Annals of Oncology. 23:ix92
Background Amrubicin hydrochloride (AMR) is a novel synthetic aminoanthracycline derivative, that is metabolically activated to amrubicinol (AMR-OH) by carbonyl reductase. The cytotoxic activity of AMR-OH is promising for small cell lung cancer and c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4e58cb5369c028e24d2291db9bb69b86
https://doi.org/10.1016/s0923-7534(20)32803-9
https://doi.org/10.1016/s0923-7534(20)32803-9